American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 761-763, May 2009

When Is Off-Label Drug Use in the Patient's Best Interest?

  • Philip J. Rosenfeld

      Affiliations

    • Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida
    • Corresponding Author InformationInquiries to Philip J. Rosenfeld, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136
    • ,
  • Kenneth W. Goodman

      Affiliations

    • Department of Medicine and Director of the Bioethics Program, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida

Accepted 26 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 See accompanying Article on page 825.

PII: S0002-9394(09)00061-0

doi:10.1016/j.ajo.2009.01.011

Refers to article:

  • Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular Degeneration , 10 February 2009

    Panagiotis G. Theodossiadis, Vasilios S. Liarakos, Petros P. Sfikakis, Ioannis A. Vergados, George P. Theodossiadis
    American Journal of Ophthalmology May 2009 (Vol. 147, Issue 5, Pages 825-830.e1)

American Journal of Ophthalmology
Volume 147, Issue 5 , Pages 761-763, May 2009

Article Tools